^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PNV21 vaccine

i
Other names: PNV21 vaccine, Neoantigen Peptide Vaccine
Associations
Company:
Fred Hutchinson Cancer Center
Drug class:
Immunostimulant
Related drugs:
Associations
4ms
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer (clinicaltrials.gov)
P1, N=20, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
Opdivo (nivolumab) • Hiltonol (poly-ICLC) • PNV21 vaccine
10ms
Trial completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • BRAF mutation • HER-2 negative • PTEN mutation + HR positive
|
Opdivo (nivolumab) • Hiltonol (poly-ICLC) • PNV21 vaccine